| Bioactivity | CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis[1]. |
| Invitro | CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC50s of 0.07 µM against triple-negative breast cancer MDA-MB-231 and 0.06 µM against ER-positive breast cancer MCF-7 cell lines, respectively[1].CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells[1].CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells[1].CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice[1]. Animal Model: |
| Name | CYD-4-61 |
| CAS | 1425944-33-7 |
| Formula | C21H17N3O3 |
| Molar Mass | 359.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu G, et al. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. Eur J Med Chem. 2019 Sep 15;178:589-605. |
CYD-4-61
CAS: 1425944-33-7 F: C21H17N3O3 W: 359.38
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-M
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.